Special Issue

Antibiofilm Activity against Multidrug-Resistant Pathogens

Message from the Guest Editors

Ninety-nine percent of bacteria exist in the form of a biofilm, which represents an emerging problem in global public health, causing great concern to the population, health professionals and the scientific community. Microbial biofilms possess intrinsic resistance against conventional antibiotics and cleaning procedures, with the capability to firmly adhere to surfaces for persistent contamination. The biofilm matrix provides bacteria with additional resistance power, which enables them to tolerate harsh conditions and also resist antimicrobials, which can lead to the spread of infections such as multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria. This Special Issue seeks manuscript submissions that improve our understanding of the process of biofilm formation in general, novel strategies for its investigation, as well as efficient agents for its treatment. Submissions on the treatment and potential eradication of biofilms using alternative antimicrobial agents (alone and in synergistic combinations) and/or novel strategies for their investigation and combined treatment to reduce their transmission and spread are especially encouraged.

Guest Editors

Dr. Verica Aleksic Sabo

Department of Biology and Ecology, Faculty of Sciences, Trg Dositeja Obradovica 3, University of Novi Sad, 21000 Novi Sad, Serbia

Prof. Dr. Petar Knezevic

Department of Biology and Ecology, Faculty of Sciences, Trg Dositeja Obradovica 3, University of Novi Sad, 21000 Novi Sad, Serbia

Deadline for manuscript submissions

31 October 2025



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/160092

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

